Vir Biotechnology, Inc. Revenue
Vir Biotechnology, Inc. (VIR) reported Revenue of $238.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-05
- Vir Biotechnology, Inc. revenues for the quarter ending 2026-06-30 was $238.95M, a 19582.54% increase year-over-year.
- Vir Biotechnology, Inc. revenues for the quarter ending 2026-03-31 was -$29.00K, a 100.96% decline year-over-year.
- Vir Biotechnology, Inc. revenues for the quarter ending 2025-12-31 was $64.07M, a 417.78% increase year-over-year.
- Vir Biotechnology, Inc. revenues for the quarter ending 2025-09-30 was $240.00K, a 89.92% decline year-over-year.
- Vir Biotechnology, Inc. revenues for fiscal 2025 was $68.56M, a 7.61% decline from fiscal 2024.
- Vir Biotechnology, Inc. revenues for fiscal 2024 was $74.20M, a 13.90% decline from fiscal 2023.
- Vir Biotechnology, Inc. revenues for fiscal 2023 was $86.18M, a 94.67% decline from fiscal 2022.
- Vir Biotechnology, Inc. revenues for fiscal 2022 was $1.62B, a 47.51% increase from fiscal 2021.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $238.95M 10-Q · filed 2026-08-05 | $238.92M 10-Q · filed 2026-08-05 | $302.99M derived: sum of 3 quarters · filed 2026-08-05 | $303.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$29.00K 10-Q · filed 2026-05-07 | $64.04M derived: sum of 2 quarters · filed 2026-05-07 | $64.28M derived: sum of 3 quarters · filed 2026-05-07 | $65.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $64.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $64.31M derived: sum of 2 quarters · filed 2026-02-23 | $65.52M derived: sum of 3 quarters · filed 2026-08-05 | $68.56M 10-K · filed 2026-02-23 |
| 2025-09-30 | $240.00K 10-Q · filed 2025-11-05 | $1.45M derived: sum of 2 quarters · filed 2026-08-05 | $4.49M 10-Q · filed 2025-11-05 | $16.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.21M 10-Q · filed 2026-08-05 | $4.25M 10-Q · filed 2026-08-05 | $16.62M derived: sum of 3 quarters · filed 2026-08-05 | $19.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.03M 10-Q · filed 2026-05-07 | $15.41M derived: sum of 2 quarters · filed 2026-05-07 | $17.79M derived: sum of 3 quarters · filed 2026-05-07 | $20.86M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $12.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $14.75M derived: sum of 2 quarters · filed 2026-02-23 | $17.83M derived: sum of 3 quarters · filed 2026-02-23 | $74.20M 10-K · filed 2026-02-23 |
| 2024-09-30 | $2.38M 10-Q · filed 2025-11-05 | $5.46M derived: sum of 2 quarters · filed 2025-11-05 | $61.83M 10-Q · filed 2025-11-05 | $78.62M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $3.08M 10-Q · filed 2025-08-06 | $59.45M 10-Q · filed 2025-08-06 | $76.24M derived: sum of 3 quarters · filed 2026-02-23 | $78.88M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $56.38M 10-Q · filed 2025-05-08 | $73.16M derived: sum of 2 quarters · filed 2026-02-23 | $75.80M derived: sum of 3 quarters · filed 2026-02-23 | $79.60M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $16.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $19.43M derived: sum of 2 quarters · filed 2026-02-23 | $23.22M derived: sum of 3 quarters · filed 2026-02-23 | $86.18M 10-K · filed 2026-02-23 |
| 2023-09-30 | $2.64M 10-Q · filed 2024-11-04 | $6.44M derived: sum of 2 quarters · filed 2024-11-04 | $69.39M 10-Q · filed 2024-11-04 | $118.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.80M 10-Q · filed 2024-08-01 | $66.75M 10-Q · filed 2024-08-01 | $116.16M derived: sum of 3 quarters · filed 2025-02-27 | $490.72M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $62.96M 10-Q · filed 2024-05-03 | $112.37M derived: sum of 2 quarters · filed 2025-02-27 | $486.92M derived: sum of 3 quarters · filed 2025-02-27 | $446.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $49.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $423.97M derived: sum of 2 quarters · filed 2025-02-27 | $383.34M derived: sum of 3 quarters · filed 2025-02-27 | $1.62B 10-K · filed 2025-02-27 |
| 2022-09-30 | $374.56M 10-Q · filed 2023-11-03 | $333.93M derived: sum of 2 quarters · filed 2023-11-03 | $1.57B 10-Q · filed 2023-11-03 | $2.38B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$40.63M 10-Q · filed 2023-08-04 | $1.19B 10-Q · filed 2023-08-04 | $2.00B derived: sum of 3 quarters · filed 2024-02-26 | $2.11B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $1.23B 10-Q · filed 2023-05-08 | $2.05B derived: sum of 2 quarters · filed 2024-02-26 | $2.15B derived: sum of 3 quarters · filed 2024-02-26 | $2.33B derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $812.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $916.36M derived: sum of 2 quarters · filed 2024-02-26 | $1.09B derived: sum of 3 quarters · filed 2024-02-26 | $1.10B 10-K · filed 2024-02-26 |
| 2021-09-30 | $103.62M 10-Q · filed 2022-11-03 | $280.68M derived: sum of 2 quarters · filed 2022-11-03 | $282.67M 10-Q · filed 2022-11-03 | $284.39M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $177.07M 10-Q · filed 2022-08-09 | $179.05M 10-Q · filed 2022-08-09 | $180.78M derived: sum of 3 quarters · filed 2022-08-09 | $182.71M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.98M 10-Q · filed 2022-05-05 | $3.71M derived: sum of 2 quarters · filed 2022-05-05 | $5.64M derived: sum of 3 quarters · filed 2022-05-05 | $72.63M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $1.73M 10-K · filed 2021-02-25 | $3.66M derived: sum of 2 quarters · filed 2021-11-04 | $70.65M derived: sum of 3 quarters · filed 2021-11-04 | $76.37M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.93M 10-Q · filed 2021-11-04 | $68.92M derived: sum of 2 quarters · filed 2021-11-04 | $74.63M 10-Q · filed 2021-11-04 | $75.61M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $66.99M 10-Q · filed 2021-08-05 | $72.71M 10-Q · filed 2021-08-05 | $73.69M derived: sum of 3 quarters · filed 2021-08-05 | $75.09M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $5.72M 10-Q · filed 2021-05-06 | $6.70M derived: sum of 2 quarters · filed 2021-05-06 | $8.10M derived: sum of 3 quarters · filed 2021-05-06 | $10.15M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $980.00K 10-K · filed 2021-02-25 | $2.38M derived: sum of 2 quarters · filed 2021-02-25 | $4.43M derived: sum of 3 quarters · filed 2021-02-25 | $8.09M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.40M 10-K · filed 2021-02-25 | $3.45M derived: sum of 2 quarters · filed 2021-02-25 | $7.11M 10-Q · filed 2020-11-10 | $10.24M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $2.05M 10-K · filed 2021-02-25 | $5.71M 10-Q · filed 2020-08-11 | $8.83M derived: sum of 3 quarters · filed 2021-02-25 | $11.72M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $3.66M 10-K · filed 2021-02-25 | $6.79M derived: sum of 2 quarters · filed 2021-02-25 | $9.67M derived: sum of 3 quarters · filed 2021-02-25 | $11.90M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $3.13M 10-K · filed 2020-03-26 | $6.01M derived: sum of 2 quarters · filed 2020-03-26 | $8.23M derived: sum of 3 quarters · filed 2020-03-26 | $10.67M 10-K · filed 2021-02-25 |
| 2018-09-30 | $2.88M 10-K · filed 2020-03-26 | $5.11M derived: sum of 2 quarters · filed 2020-03-26 | $7.54M 10-Q · filed 2019-11-19 | |
| 2018-06-30 | $2.22M 10-K · filed 2020-03-26 | $4.66M derived: sum of 2 quarters · filed 2020-03-26 | ||
| 2018-03-31 | $2.43M 10-K · filed 2020-03-26 | |||
| 2017-12-31 | $2.71M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |